Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 2/20 | 0.36 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.31 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.31 |
| ▸ | ITGAL | P20701 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | GSK3A | P49840 | 1/20 | 0.30 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | THPO | P40225 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL543719 | 0.82 | CYP19A1 (0.33) | ELANE | |
| SCHEMBL543867 | 0.77 | ELANE (0.37) | ELANEITGB2ICAM1ITGALALDH1A1 | |
| SCHEMBL543513 | 0.71 | ALDH1A1 (0.48) | ELANEALDH1A1GSK3AGSK3BBACE1 | |
| SCHEMBL543781 | 0.70 | CNR1 (0.40) | ELANECYP1A2CYP2C9CYP2C19 | |
| SCHEMBL893095 | 0.70 | ELANE (0.35) | ELANE | |
| SCHEMBL543659 | 0.69 | ELANE (0.37) | ELANEALDH1A1BACE1 | |
| SCHEMBL543845 | 0.69 | ELANE (0.34) | ELANEALDH1A1BACE1 | |
| Hydrochloric Acid SCHEMBL892604 | 0.68 | ELANE (0.33) | ELANEALDH1A1BACE1 | |
| SCHEMBL544423 | 0.66 | ELANE (0.35) | ELANEALDH1A1 | |
| SCHEMBL544341 | 0.66 | ELANE (0.34) | ELANEITGB2ICAM1ITGALGSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2388002-B1 | Antidepressant containing heterocyclic compound having specific structure | ZENYAKU KOGYO KK (JP) | 2013-03-13 | — | — | EP | claimed |
| EP-2388002-A2 | Antidepressant containing heterocyclic compound having specific structure | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2011-11-23 | — | — | EP | claimed |
| US-8040824-B2 | Methods and apparatus for content delivery via application level multicast with minimum communication delay | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2011-10-18 | — | — | US | claimed |
| US-20110059998-A1 | KIT, COMPOSITION, PRODUCT OR MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT | ZENYAKU KOGYO KABUSHIKI KAISHA | 2011-03-10 | — | — | US | claimed |
| EP-2257290-A1 | KIT, COMPOSITION, PRODUCT OR MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2010-12-08 | — | — | EP | claimed |
| US-7767824-B2 | Heterocyclic compounds and cerebral function improvers containing the same as the active ingredient | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2010-08-03 | — | — | US | claimed |
| WO-2009107401-A1 | KIT, COMPOSITION, PRODUCT OR MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2009-09-03 | — | — | WO | claimed |
| US-20090221554-A1 | METHOD OF TREATING COGNITIVE IMPAIRMENT | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2009-09-03 | — | — | US | claimed |
| EP-2077836-A2 | ANTIDEPRESSANT, NEUROPROTECTANT, AMYLOID BETA DEPOSITION INHIBITOR OR AGE RETARDANT CONTAINING HETEROCYCLIC COMPOUND | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2009-07-15 | — | — | EP | claimed |
| EP-2077835-A2 | AN ALZHEIMER'S DISEASE PROGRESSION INHIBITOR CONTAINING HETEROCYCLIC COMPOUND | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2009-07-15 | — | — | EP | claimed |
| US-20080103157-A1 | 3,3-dibenzylimidazo[1,2-a]pyridin-2(3H)-one; antidepressant, neuroprotectant, antiaging agent; manic depressive psychoses, obsessive-compulsive disorder; orally | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2008-05-01 | — | — | US | claimed |
| WO-2008047951-A2 | AN ALZHEIMER' S DISEASE PROGRESSION INHIBITOR CONTAINING HETEROCYCLIC COMPOUND | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2008-04-24 | — | — | WO | claimed |
| WO-2008047952-A2 | ANTIDEPRESSANT, NEUROPROTECTANT, AMYLOID BETA DEPOSITION INHIBITOR OR AGE RETARDANT CONTAINING HETEROCYCLIC COMPOUND | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2008-04-24 | — | — | WO | claimed |
| US-20060205742-A1 | Heterocyclic compounds and cerebral function improvers containing the same as the active ingredient | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2006-09-14 | — | — | US | claimed |
| EP-1357124-B1 | HETEROCYCLIC COMPOUNDS AND CEREBRAL FUNCTION IMPROVERS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ZENYAKU KOGYO KK (JP) | 2005-08-03 | — | — | EP | claimed |
| US-20040048879-A1 | Heterocyclic compounds and cerebral function improvers containing the same as the active ingredient | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2004-03-11 | — | — | US | claimed |
| EP-1357124-A1 | HETEROCYCLIC COMPOUNDS AND CEREBRAL FUNCTION IMPROVERS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2003-10-29 | — | — | EP | claimed |
| EP-2388000-B1 | Neuroprotectant containing heterocyclic compound having specific structure | ZENYAKU KOGYO KK (JP) | 2016-04-06 | — | — | EP | disclosed |
| US-20040048879-A1 | Heterocyclic compounds and cerebral function improvers containing the same as the active ingredient | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2004-03-11 | — | — | US | disclosed |
| EP-1357124-A1 | HETEROCYCLIC COMPOUNDS AND CEREBRAL FUNCTION IMPROVERS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2003-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205742-A1 | Heterocyclic compounds and cerebral function improvers containing the same as the active ingredient | CBR3, CBR1, C1R | ELANE 3133/4885ITGB2 4823/4885ICAM1 4458/4885 |
| US-20080103157-A1 | 3,3-dibenzylimidazo[1,2-a]pyridin-2(3H)-one; antidepressant, neuroprotectant, antiaging agent; manic depressive psychoses, obsessive-compulsive disorder; orally | PSEN1, PSEN2, BDNF | ELANE 2190/4885ITGB2 2308/4885ICAM1 2419/4885 |
| US-20110059998-A1 | KIT, COMPOSITION, PRODUCT OR MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT | KIT, CHAT, BDNF | ELANE 3388/4885ITGB2 4838/4885ICAM1 4618/4885 |
| US-20040048879-A1 | Heterocyclic compounds and cerebral function improvers containing the same as the active ingredient | CBR1, CBR3, CHAT | ELANE 3938/4885ITGB2 4433/4885ICAM1 3057/4885 |
| US-20090221554-A1 | METHOD OF TREATING COGNITIVE IMPAIRMENT | CHAT, ACHE, BCHE | ELANE 1639/4885ITGB2 4536/4885ICAM1 4184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.